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Abstract
Lysosomal acid lipase (LAL) plays a key role in intracellular lipid metabolism.
Reduced LAL activity promotes increased multi-organ lysosomal cholesterol
ester storage, as observed in two recessive autosomal genetic diseases, Wolman
disease and Cholesterol ester storage disease. Severe liver steatosis and
accelerated liver fibrosis are common features in patients with genetic LAL
deficiency. By contrast, few reliable data are available on the modulation of LAL
activity in vivo and on the epigenetic and metabolic factors capable of regulating
its activity in subjects without homozygous mutations of the Lipase A gene. In
the last few years, a less severe and non-genetic reduction of LAL activity was
reported in children and adults with non-alcoholic fatty liver disease (NAFLD),
suggesting a possible role of LAL reduction in the pathogenesis and progression
of the disease. Patients with NAFLD show a significant, progressive reduction of
LAL activity from simple steatosis to non-alcoholic steatohepatitis and
cryptogenic cirrhosis. Among cirrhosis of different etiologies, those with
cryptogenic cirrhosis show the most significant reductions of LAL activity. These
findings suggest that the modulation of LAL activity may become a possible new
therapeutic target for patients with more advanced forms of NAFLD. Moreover,
the measurement of LAL activity may represent a possible new marker of disease
severity in this clinical setting.
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Core tip: Reduced lysosomal acid lipase (LAL) activity promotes increased multi-organ
lysosomal cholesterol ester storage, as observed in two recessive autosomal genetic
diseases, Wolman disease and Cholesterol ester storage disease. A less severe and non-
genetic reduction of LAL activity has been reported in children and adults with non-
alcoholic fatty liver disease (NAFLD). Patients with NAFLD show a significant,
progressive reduction of LAL activity from simple steatosis to non-alcoholic
steatohepatitis and cryptogenic cirrhosis. In the future, modulation of LAL activity may
become a possible new therapeutic target for patients with more advanced forms of
NAFLD and represent a possible new marker of disease severity.
Citation: Baratta F, Pastori D, Ferro D, Carluccio G, Tozzi G, Angelico F, Violi F, Del Ben
M. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the
clinical continuum of non-alcoholic fatty liver disease? World J Gastroenterol 2019; 25(30):
4172-4180
URL: https://www.wjgnet.com/1007-9327/full/v25/i30/4172.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i30.4172
INTRODUCTION
Lysosomal acid lipase (LAL) is a key enzyme for intracellular lipid metabolism, which
regulates the intra-lysosomal hydrolysis of cholesterol esters (CE) and triglycerides
(TG), producing free cholesterol and fatty acids[1]. The LAL activity reduction causes
intra-lysosomal accumulation of CE and lowers free cholesterol in cytosol[2].  This
reduction increases transcription factor sterol regulatory element binding protein
activity, which promotes lipogenesis and synthesis of cholesterol and of very low-
density lipoproteins. In addition, there is a reduction in liver X receptors expression
resulting  in  impaired  cholesterol  efflux  and  high-density  lipoprotein  (HDL)
production[3]. Moreover, low-density lipoprotein (LDL) receptor synthesis and the
receptor-mediated LDL uptake are amplified.
In patients with both heterozygous or homozygous deletion of lipase A (LIPA)
gene,  a  lipid  phenotype  similar  to  that  observed  in  patients  with  familial
hypercholesterolemia  (FH)  has  been  described[4,5].  Therefore,  in  presence  of
hypercholesterolemia with type IIa phenotype, it is very important, but not always
easy,  to make a differential  diagnosis  with heterozygous FH (Table 1).  A family
history for early cardiovascular disease and/or hypercholesterolemia supports a
diagnosis of heterozygous FH. On the contrary, in the absence of diagnostic criteria
for  FH,  a  LAL  defect  could  be  suspected,  especially  in  patients  with  hyper-
cholesterolemia associated with low levels of HDL cholesterol. The Dutch Lipid Clinic
Network score[6,7] or the Simon Broome criteria[8] for FH may be two useful tools for a
differential diagnosis.
GENETICS OF LAL DEFICIENCY
LAL  deficiency  (LAL-D)  is  a  rare  autosomal  recessive  genetic  disease  due  to  a
mutation in the LIPA gene, characterized by the presence of CE and TG in numerous
tissues. The most common mutation is the E8SJM variant, which has an estimated
frequency of 0.00025 in the general population (i.e., 1 carrier per 200 individuals in
Western countries). The LAL-D is a heterogeneous disorder that may present with
two different phenotypes based on residual LAL activity levels (Figures 1): Wolman’s
disease and cholesterol ester storage disease (CESD)[1,4].
Wolman’s disease starts prematurely during the 6th or 7th mo of life and quickly
leads to death, with only a small proportion of patients surviving beyond the first
year  of  age.  Infants  with LAL-D show delayed growth,  associated with signs of
malabsorption, hepatosplenomegaly, severe hepatic dysfunction, rapidly progressive
anemia, and multi-organ failure; the adrenal calcifications are the pathognomonic sign
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Figure 1
Figure 1  LAL activity reduction in the spectrum of NAFLD. LAL: Lysosomal acid lipase; NAFLD: Non-alcoholic
fatty liver disease; NASH: Non-alcoholic steatohepatitis; CESD: Cholesterol esters storage disease.
of Wolman’s disease. In these patients, LAL activity is almost null[1].
CESD is the late onset phenotype, being manifested during childhood, adolescence,
or in adulthood, with onset age ranging from 5 to 44 years or more. It presents with
hepatic steatosis, high levels of aminotransferase, hepatomegaly, and dyslipidemia.
As the clinical manifestations of CESD are not very characteristic, the diagnosis is
often occasional. The clinical phenotype and disease severity are very variable and
depend on the residual enzymatic activity, which is usually less than 12%. Therefore,
the coexistence of hepatic steatosis and hypercholesterolemia, in particular in non-
obese subjects, should lead to the differential diagnosis between LAL-D and other
metabolic causes of non-alcoholic fatty liver disease (NAFLD), such as metabolic
syndrome, type II diabetes, hypertriglyceridemia, and central obesity[9].
LIVER ALTERATIONS IN LAL-D
LAL-D  leads  to  CE  and  TG  accumulation  in  hepatocytes  and  liver-resident
macrophages (Kupffer cells) with subsequent progression to fibrosis (Figures 2). The
high prevalence of severe fibrosis in LAL-D and its rapid progression to cirrhosis
suggest that lysosomal CE and TG accumulation is a potent driver of liver fibrosis[9-11].
A recent study showed increased transaminases in hepatocyte-specific LAL-deficient
mice (Liv-Lipa -/-) as well as upregulation of hepatic cytokines and chemokines,
known  to  drive  inflammation  and  leading  to  Kupffer  cell  activation  and  liver
damage[12]. In addition, lysosomal CE accumulation induces Kupffer cell activation,
causing inflammation and liver damage in high fat/high cholesterol fed Liv-Lipa-/-
mice. These findings indicated that hepatocytes’ LAL plays a critical role for liver
homeostasis and function.
A recent study reported data on allograft recurrence, liver failure, and other clinical
outcomes in  18  liver  transplantation (LT)  LAL-D patients.  LT was necessary for
treatment of LAL-D-associated liver failure but, interestingly, did not correct LAL
activity, which remained deficient post-LT[13]. Therefore, LT does not correct deficient
LAL  enzyme  in  bone  marrow  derived  histiocytes;  moreover,  LT  does  not  even
prevent multi-organ disease progression or liver disease recurrence, as observed in
liver biopsies within the first year following LT.
In  addition,  Burton  et  al[14]  have  shown  how,  in  patients  with  genetic  LAL
deficiency, 20 wk treatment with enzyme replacement therapy (Sebelipase-alpha) is
able to reduce hepatic  fat  evaluated by magnetic  resonance.  In addition,  treated
patients showed serum liver enzymes and serum lipids improvement.
LAL ACTIVITY REDUCTION AND NAFLD
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Figure 2
Figure 2  Changes of hepatic lipid metabolism in lysosomal acid lipase deficiency. Reduced lysosomal acid
lipase activity causes lysosomal lipid accumulation and reduction of free fatty acids and cholesterol in cytosol. This
reduction influences numerous gene transcriptions via transcription factors such as liver X receptors and steroid
regulation binding proteins, resulting in higher expression of low-density lipoprotein receptor, acetyl-coenzyme A
acetyltransferase, and 3-idrossi-3-metilglutaril-coenzima A reductase and in a lower expression of ATP-binding
cassette A1. These changes result in amplified lysosomal lipid accumulation, increased serum very low-density
lipoproteins, and decreased serum high-density lipoprotein. LAL: Lysosomal acid lipase; ACAT: Acetyl-coenzyme A
acetyltransferase; HMGCoA: 3-Idrossi-3-metilglutaril-coenzima A; LXRs: Liver X receptors; SREBPs: Steroid
regulation binding proteins; ABCA1: ATP-binding cassette A1; LDL: Low-density lipoprotein; VLDL: Very low-density
lipoproteins; HDL: High-density lipoprotein; LDL-r: Low-density lipoprotein receptor.
The term NAFLD indicates a set of diseases associated with the presence of excessive
accumulation of hepatic fat in the absence of chronic viral infection and alcohol abuse.
NAFLD is the most common hepatic disease. It is estimated that the prevalence in the
general population is about 20%-30%, reaching up to 70%-90% in the obese or diabetic
population[15].
NAFLD, in the initial phases, presents as simple steatosis, whose main histological
finding  is  the  presence  of  predominantly  macrocytic  steatosis  in  at  least  5%  of
hepatocytes. In some cases, simple steatosis evolves into non-alcoholic steatohepatitis
(NASH),  in  which  the  histological  picture  includes  steatosis,  ballooning,  and
inflammation  with  a  progressive  increase  in  fibrosis.  In  the  past,  NAFLD  was
considered a benign condition; however, recent evidence suggests a less favorable
prognosis, due to the possible evolution in cirrhosis, hepatocellular carcinoma, and
hepatic  failure[16].  Today,  NAFLD  is  considered  the  main  cause  of  cryptogenic
cirrhosis, the prevalence of which is increasing in recent years, especially in patients
with history of obesity and type II diabetes. NAFLD is the second indication for liver
transplantation in the US and is expected to exceed hepatitis C virus (HCV) in the
next few years, becoming the first cause for liver transplant[17].
Numerous  pathogenic  factors  contribute  to  the  accumulation  of  lipids  in  the
hepatocytes and, in a proportion of patients, the development of fibrotic processes[18].
Among them, insulin resistance, oxidative stress, and low-grade chronic inflammation
supported by the production of cytokines deriving from visceral fat. However, the
pathogenic mechanisms underlying the progression of simple steatosis to NASH and
cirrhosis are not yet fully clarified nor are tools available to predict the evolution of
NAFLD.
Prospective studies suggest that the first cause of death in patients diagnosed with
NAFLD is  cardiovascular  disease[19,20].  Atherosclerosis  is  very  common in  these
subjects, and many of them, especially before the onset of liver complications, develop
coronary heart disease[21]. The relationship between NAFLD and cardiovascular risk
has long been investigated[15,22-24].
According to the "multiple parallel hits hypothesis", many insults, including insulin
resistance,  the  presence  of  gene  variants,  oxidative  stress,  and  alteration  of  the
intestinal microbiota, act simultaneously on the liver causing lipid infiltration and
inflammation[18]. It remains to be clarified whether it is the metabolic syndrome that
promotes steatosis through insulin resistance, or whether it is NAFLD that induces
hyperinsulinemia through a defective mechanism of insulin degradation. The current
opinion suggests a bidirectional link between NAFLD and the metabolic syndrome[25].
Few studies have so far assessed the activity of LAL in patients with NAFLD, and
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Table 1  Lipid phenotype of patients presenting with genetic dyslipidemia or LAL-related
dyslipidemia
Disease TC LDL HDL TG Phenotype
LAL-related dyslipidemia ↑↑↑ ↑↑↑ ↓ ↑ IIa, IIb,
Familial hypercholesterolemia ↑↑↑ ↑↑↑ =/↓ = IIa, IIb
Familial combined hyperlipidemia ↑↑ ↑↑ ↓ ↑ IIa, IIb, IV, V
Familial hypertriglyceridemia N/ ↓ ↓↓ ↑↑ IV, V
Type III hyperlipidemia (dysbetalipoproteinemia) ↑↑ ↓ = ↑↑ III, IV
Iperchylomicronemia ↑ ↓ ↓↓↓ ↑↑↑ I, V
Hypoalfalipoproteinemia N/↓ N ↓↓↓↓ N Low HDL
LAL: Lysosomal acid lipase; LDL: Low-density lipoprotein; HDL: High-density lipoprotein.
the possible role of LAL as one of the multiple hits in NAFLD pathogenesis is under
debate[26].
Our group[27]  has recently demonstrated reduced LAL activity in patients with
NAFLD.  LAL  activity  was  significantly  reduced  in  240  patients  with  NAFLD
compared to 100 heathy subjects (HS) [0.78 (0.61-1.01) nmol/spot per hour vs 1.15
(0.94-1.72) nmol/spot per hour, P  < 0.001].  An even more marked reduction was
observed in patients with histologically diagnosed NASH [0.67 (0.51-0.77) nmol/spot
per hour, P < 0.001 vs HS; P < 0.001, between the groups]. In addition, patients with
NAFLD who exhibited enzymatic activity below the median had higher serum total
cholesterol  (P  <  0.05)  and  LDL  cholesterol  (P  <  0.05)  and  higher  levels  of
transaminases and gamma-glutamyltransferase (alanine aminotransferase, P < 0.001;
aspartate aminotransferase, P < 0.01; gamma-glutamyltransferase, P < 0.01).
Therefore, based on our findings, it was possible to hypothesize that the reduction
of LAL activity, as well as a predisposing factor for the development of NAFLD, could
be considered as a further pathophysiological mechanism for progression to NASH
and eventually to cryptogenic cirrhosis. Moreover, based on the above observations[28],
we could also hypothesize that LAL activity can constitute a possible tool for the
identification of the subjects with more advanced forms of NAFLD and possibly for
the monitoring of the response to therapy.
Shortly thereafter[29], a significant reduction in LAL activity in a series of pediatric
cases was also observed. In this study, children with significant fibrosis (stage 2-3, n =
64) had a significantly lower LAL activity compared to those with mild fibrosis (stage
0-1, n = 104), suggesting a potential role of reduced LAL activity in the pathogenesis
of NAFLD-induced fibrosis.
In a further study[30], we found that NAFLD patients disclosed a relatively high
prevalence  of  spleen  enlargement  and  splenomegaly,  which  were  significantly
associated with a reduced LAL activity, suggesting that LAL may contribute to spleen
enlargement in this setting. Although the degree of LAL activity reduction was less
pronounced compared to genetic forms of LAL deficiency, which develop severe fat
accumulation in the spleen, a similar mechanism may be hypothesized.
More recently, Tovoli et al[31] performed a study of LAL activity in 81 patients with a
diagnosis of NAFLD and 78 matched controls with HCV-related liver disease. LAL
activity was significantly reduced in NAFLD compared to that  in HCV patients,
suggesting that NAFLD is characterized by a specific deficit in LAL activity.
Finally,  in  a  study by Gomaraschi  M et  al[32],  164  patients  with biopsy-proven
NAFLD were compared with 60 dyslipidemic patients with similar prevalence of
metabolic syndrome and 30 controls. LAL activity on dried blood spot (DBS) was
reduced in NAFLD patients compared to controls and those with dyslipidemia.
Therefore, we may conclude that the reduction of LAL activity, even in the absence
of genetic diseases, seemed to be associated with the development of progressive
hepatic steatosis (Table 2).
LAL-D AND LIVER CIRRHOSIS
Based on follow-up studies, 25% of patients affected by NASH may develop cirrhosis
and  eventually  hepatocellular  carcinoma.  In  fact,  current  knowledge  strongly
indicates that cryptogenic cirrhosis is, in truth, the evolution of NASH. However, the
mechanisms underlying disease progression remain poorly understood. Following
evidence  from NAFLD,  we hypothesized that  epigenetic  and/or  environmental
WJG https://www.wjgnet.com August 14, 2019 Volume 25 Issue 30
Baratta F et al. Reduced lysosomal acid lipase activity
4176
Table 2  Studies investigating the activity of lysosomal acid lipase in patients with non-alcoholic fatty liver disease and liver cirrhosis
NAFLD
Year Paper Study populations Results1 Conclusions
2015 Baratta et al[27] 100 HS; 240 NAFLD patients;
(35 biopsy-proven NASH)
Median LAL activity was:
1.15 (0.95-1.72) in HS; 0.78
(0.61-1.01) in NAFLD; 0.67
(0.51-0.77) in NASH
A significant reduction of
LAL activity in NAFLD
patients compared to HS. In
particular, in the subgroup of
patients with biopsy proven
NASH
2016 Selvakumar et al[29] 168 children with biopsy-
proven NAFLD; (80 NAFL
and 88 NASH)
Mean LAL activity was: 1.3 ±
0.57 in NAFL patients; 1.2 ±
0.80 in NASH patients; 1.4 ±
0.80 in patients with F0-F1;
1.1 ± 0.45 in patients with F2-
F3
No significant difference in
LAL activity between
children with NASH
compared to those without
NASH; Reduced blood LAL
activity correlates with
severity of liver fibrosis
2017 Polimeni et al[30] 315 NAFLD patients; with US
spleen dimensions evaluation
Median LAL activity was: 0.9
(0.7-1.2) in patients with
normal spleen; 0.7 (0.6-0.9) in
patients with splenomegaly
Spleen enlargement and
splenomegaly were
significantly associated with
a reduced LAL activity
2017 Tovoli et al[31] 81 NAFLD patients; (53.1%
with cirrhosis)
Median LAL activity was:
0.55 (0.41-0.81) in non-
cirrhotic NAFLD patients;
0.84 (0.69-1.07) in non-
cirrhotic HCV patients
LAL activity is significantly
reduced in non-cirrhotic
NAFLD, compared to that in
non-cirrhotic HCV patients.
78 HCV patients (59.0% with
cirrhosis)
Liver cirrhosis
2016 Vespasiani-Gentilucci et al[34] 63 CC patients 88 KAC
patients 97 HS
Median LAL activity: 0.62
(0.44-0.86) in CC patients;
0.54 (0.42-0.79) in KAC
patients; 0.96 (0.75-1.25) in HS
Liver cirrhosis is
characterized by a severe
acquired reduction of LAL-
activity; The difference
between the two groups of
cirrhotics was not significant
[…]; LAL activity was not
associated with liver function
as determined with Child-
Pugh class […]
2016 Shteyer et al[35] 22 patients aged 1-75 years
who underwent liver biopsy;
13 at high risk for LAL-D
(microvesicular steatosis or
with cryptogenic cirrhosis); 9
at low risk for LAL-D;
(microvesicular steatosis in
metabolic/NAFLD patients)
Mean LAL activity was 0.74 ±
0.28 and was similar in both
risk groups; 37.5% had LAL <
0.5
LAL < 0.5 was associated
with markers of liver disease
severity
2017 Tovoli et al[31] 81 NAFLD patients; (53.1%
with cirrhosis)
Median LAL activity was:
0.53 (0.29-0.69) in cirrhotic
NAFLD patients; 0.67 (0.50-
0.89) in cirrhotic HCV
patients
LAL activity is significantly
reduced in NAFLD-related
cirrhosis compared to HCV-
cirrhosis
78 HCV patients; (59.0% with
cirrhosis)
2017 Angelico et al[33] 133 CC patients; 141 KAC
patients
Median LAL activity was:
0.49 (0.38-0.75) in CC
patients; 0.65 (0.46-0.94) KAC
patients
A strong association between
LAL activity reduction and
severity of liver disease was
found. A marked reduction of
LAL activity in patients with
cryptogenic cirrhosis
compared to the other known
etiologies despite a more
severe liver disease in the
latter
1All lysosomal acid lipase activity values are expressed as nmol/spot per hour. HS: Healthy subjects; NAFLD: Non-alcoholic fatty liver disease; NAFL:
Non-alcoholic fatty liver/simple steatosis; NASH: Non-alcoholic steatohepatitis; CC: Cryptogenic cirrhosis; KAC: Known etiology cirrhosis.
modulation of LAL activity could be also an unrecognized contributing factor in the
progression to cryptogenic cirrhosis.
To evaluate a possible role of LAL in cryptogenic cirrhosis, we carried out a cohort
study including 274 patients with liver cirrhosis of different etiology from 19 centers
in Italy[33]. Median LAL activity value was 0.58 nmol/spot per hour, 0.49 and 0.65 in
the cryptogenic cirrhosis and alcoholic/viral cirrhosis groups, respectively (P < 0.002).
Approximately 30% of patients with cryptogenic cirrhosis showed a severe reduction
WJG https://www.wjgnet.com August 14, 2019 Volume 25 Issue 30
Baratta F et al. Reduced lysosomal acid lipase activity
4177
of LAL activity (i.e., < 0.40 nmol/spot per hour). The reduction was more evident in
patients with cryptogenic cirrhosis, despite less severe liver disease. Furthermore, we
observed a strong association between LAL activity reduction and severity of liver
disease assessed by Child-Turcotte-Pugh and Model for End-Stage Liver Disease
scores.
In a further single-center study carried out by Vespasiani-Gentilucci et al[34] , LAL-
activity was severely reduced in patients with cryptogenic cirrhosis with respect to
healthy subjects (HS) [0.62 (0.44-0.86) vs  0.96 (0.75-1.25) nmol/spot per hour, P  <
0.001)],  but  it  was  also  reduced  in  known-etiology  cirrhotics  [0.54  (0.42-0.79)
nmol/spot per hour, P < 0.001 vs HS]. In this study, authors sequenced the LIPA gene
and excluded genetic etiology for the observed LAL reduction.
Shteyer  et  al[35]  performed  a  study  on  medical  records  of  22  patients  with
microvescicular steatosis and cryptogenic cirrhosis and 9 with NAFLD diagnosed
with liver biopsies. LAL activity inversely predicted liver disease severity, and LAL
level of 0.5 was the most sensitive for detecting both histologic and non-invasive
markers for disease severity (Table 2).
WHOM TO MEASURE LAL ACTIVITY?
LAL-D should be suspected in non-obese subjects with NAFLD and/or cryptogenic
cirrhosis,  unexplained persistently elevated levels of transaminases, and/or high
levels of LDL cholesterol and low HDL cholesterol.
In these subjects, it would be appropriate to measure LAL activity using the DBS
test, which is a simple and inexpensive test that determines the enzymatic activity on
the blood spot, subtracting from the activity of the total lipase obtained after addition
of a specific LAL inhibitor (Lalistat 2). All patients with a marked reduction in LAL
activity (≤ 0.4 nmol/spot per hour) should be investigated for the presence of LIPA
gene mutations. Patients homozygous for LAL deficiency have a residual activity
equal to or close to 0. The lower limit of the range of normality in the validation tests
of the method was 0.8 nmol/spot per hour.
CONCLUSION
A reduced LAL activity may contribute to liver damage in patients with NAFLD, but
several issues need to be addressed to better understand the role of LAL in liver
diseases.  First,  there  are  no reliable  in  vivo  data  on LAL activity  modulation.  In
particular, epigenetic and environmental factors that are able to regulate its activity in
subjects  without  homozygous  mutations  of  the  LIPA  gene  have  not  yet  been
identified. For example, it is not known whether an intervention on modifiable cardio-
metabolic risk factors, typically associated with NAFLD, such as metabolic syndrome,
diabetes, overweight, or oxidative stress, may affect the modulation of LAL activity in
a favorable manner. Moreover, it is still unclear whether low LAL activity may predict
liver disease progression and or cardio-metabolic events.
Besides, the specific contribution of circulating cells to the total activity of LAL on
the DBS test  is  still  unclear.  In a study of a random sample of  300 subjects,  LAL
activity, measured with 4-methyl-umbelliferyl oleate as the substrate, was present in
high concentration in lymphocytes and monocytes but not in polymorphonuclear
leukocytes[36]. Recently, in a study performed in 172 HS aged ≥ 18 years, LAL activity
in white blood cells was significantly higher than in platelets (458.9 ± 133.6 nmol/mg
per hour vs 235.0 ± 88.3 nmol/mg per hour, P < 0.001). However, LAL activity in DBS
correlated more strongly with that  in  platelets,  suggesting that  platelet  count  is
recommended before interpreting LAL activity in DBS[37].
In addition, it remains to be clarified whether any improvement in the enzymatic
activity could result in a reduction of hepatic fat in patients with NAFLD. In light of
the results of a recent clinical trial with Sebelipase-alfa, it can be hypothesized that the
modulation of LAL activity may become a possible new therapeutic target in the
future, even in conditions of less severe reductions of LAL activity[14].  This could
mainly concern patients with more advanced forms of NAFLD, such as those with
NASH  or  cryptogenic  cirrhosis  for  which,  at  present,  there  are  no  effective
therapies[33,38].
In conclusion, the measurement of LAL activity in patients with NAFLD may be a
new non-invasive marker of liver disease severity.
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